260 related articles for article (PubMed ID: 32249621)
1. Cost-effectiveness of once weekly carfilzomib 70 mg/m2 plus dexamethasone in patients with relapsed and refractory multiple myeloma in the United States.
Kumar SK; Majer I; Panjabi S; Medhekar R; Campioni M; Dimopoulos MA
Expert Rev Hematol; 2020 Jun; 13(6):687-696. PubMed ID: 32249621
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective.
Jakubowiak AJ; Campioni M; Benedict Á; Houisse I; Tichy E; Giannopoulou A; Aggarwal SK; Barber BL; Panjabi S
J Med Econ; 2016 Nov; 19(11):1061-1074. PubMed ID: 27224006
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States.
Jakubowiak AJ; Houisse I; Májer I; Benedict Á; Campioni M; Panjabi S; Ailawadhi S
Expert Rev Hematol; 2017 Dec; 10(12):1107-1119. PubMed ID: 29027825
[TBL] [Abstract][Full Text] [Related]
4. Once-weekly (70 mg/m
Moreau P; Stewart KA; Dimopoulos M; Siegel D; Facon T; Berenson J; Raje N; Berdeja JG; Orlowski RZ; Yang H; Ma H; Klippel Z; Zahlten-Kumeli A; Mezzi K; Iskander K; Mateos MV
Cancer Med; 2020 May; 9(9):2989-2996. PubMed ID: 32108443
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed-refractory Multiple Myeloma in the United States.
Pelligra CG; Parikh K; Guo S; Chandler C; Mouro J; Abouzaid S; Ailawadhi S
Clin Ther; 2017 Oct; 39(10):1986-2005.e5. PubMed ID: 28967482
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma.
Facon T; Niesvizky R; Mateos MV; Siegel D; Rosenbaum C; Bringhen S; Weisel K; Ho PJ; Ludwig H; Kumar S; Wang K; Obreja M; Yang Z; Klippel Z; Mezzi K; Goldrick A; Tekle C; Dimopoulos MA
Blood Adv; 2020 Nov; 4(21):5449-5459. PubMed ID: 33166401
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of Drugs to Treat Relapsed/Refractory Multiple Myeloma in the United States.
Carlson JJ; Guzauskas GF; Chapman RH; Synnott PG; Liu S; Russo ET; Pearson SD; Brouwer ED; Ollendorf DA
J Manag Care Spec Pharm; 2018 Jan; 24(1):29-38. PubMed ID: 29290170
[TBL] [Abstract][Full Text] [Related]
8. Economic Evaluation of Adding Daratumumab to a Regimen of Bortezomib + Dexamethasone in Relapsed or Refractory Multiple Myeloma: Based on the Latest Updated Analysis of CASTOR.
Zeng X; Peng L; Peng Y; Tan C; Wan X
Clin Ther; 2020 Feb; 42(2):251-262.e5. PubMed ID: 31973936
[TBL] [Abstract][Full Text] [Related]
9. Convenience, satisfaction, health-related quality of life of once-weekly 70 mg/m
Moreau P; Kumar S; Boccia R; Iida S; Goldschmidt H; Cocks K; Trigg A; Zahlten-Kumeli A; Yucel E; Panjabi SS; Dimopoulos M
Leukemia; 2019 Dec; 33(12):2934-2946. PubMed ID: 31092895
[TBL] [Abstract][Full Text] [Related]
10. A descriptive cost-analysis of MYX.1/MCRN003, a phase 2 clinical trial evaluating high-dose weekly carfilzomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma.
Monteith BE; Venner CP; Cheung MC; Pater J; Shepherd L; Richardson H; Reece D; Gul E; Lalancette M; Castonguay V; Kukreti V; Tiedemann R; Phua C; Bhella S; Dudebout J; Sherry M; Yen H; Chen BE; Hay AE
Eur J Haematol; 2021 Sep; 107(3):333-342. PubMed ID: 34053112
[TBL] [Abstract][Full Text] [Related]
11. CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma.
Berenson JR; Cartmell A; Bessudo A; Lyons RM; Harb W; Tzachanis D; Agajanian R; Boccia R; Coleman M; Moss RA; Rifkin RM; Patel P; Dixon S; Ou Y; Anderl J; Aggarwal S; Berdeja JG
Blood; 2016 Jun; 127(26):3360-8. PubMed ID: 27207788
[TBL] [Abstract][Full Text] [Related]
12. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
Moreau P; Mateos MV; Berenson JR; Weisel K; Lazzaro A; Song K; Dimopoulos MA; Huang M; Zahlten-Kumeli A; Stewart AK
Lancet Oncol; 2018 Jul; 19(7):953-964. PubMed ID: 29866475
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma.
Usmani SZ; Cavenagh JD; Belch AR; Hulin C; Basu S; White D; Nooka A; Ervin-Haynes A; Yiu W; Nagarwala Y; Berger A; Pelligra CG; Guo S; Binder G; Gibson CJ; Facon T
J Med Econ; 2016; 19(3):243-58. PubMed ID: 26517601
[TBL] [Abstract][Full Text] [Related]
14. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
Dimopoulos MA; Goldschmidt H; Niesvizky R; Joshua D; Chng WJ; Oriol A; Orlowski RZ; Ludwig H; Facon T; Hajek R; Weisel K; Hungria V; Minuk L; Feng S; Zahlten-Kumeli A; Kimball AS; Moreau P
Lancet Oncol; 2017 Oct; 18(10):1327-1337. PubMed ID: 28843768
[TBL] [Abstract][Full Text] [Related]
15. Cost Effectiveness of Triplet Selinexor-Bortezomib-Dexamethasone (XVd) in Previously Treated Multiple Myeloma (MM) Based on Results from the Phase III BOSTON Trial.
Dolph M; Tremblay G; Leong H
Pharmacoeconomics; 2021 Nov; 39(11):1309-1325. PubMed ID: 34368938
[TBL] [Abstract][Full Text] [Related]
16. A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China.
Du J; Fang B; Li J; Jin J; Wang S; Zou D; Cai Z; Wang H; Hu J; Li W; Fu C; Shao Z; Xia Z; Liu P; Niu T; Tang ET; Kimball AS; Hou J; Chen W
Int J Hematol; 2021 Mar; 113(3):422-429. PubMed ID: 33389656
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of pomalidomide in patients with relapsed and refractory multiple myeloma in Sweden.
Borg S; Nahi H; Hansson M; Lee D; Elvidge J; Persson U
Acta Oncol; 2016 May; 55(5):554-60. PubMed ID: 27123742
[TBL] [Abstract][Full Text] [Related]
18. Estimating the Economic Impact of Adding Panobinostat to a U.S. Formulary for Relapsed and/or Refractory Multiple Myeloma: A Budget Impact and Cost-Benefit Model.
Bloudek L; Roy A; Kish JK; Siegel DS; Jagannath S; Globe D; Orloski L; Kuriakose ET
J Manag Care Spec Pharm; 2016 Aug; 22(8):991-1002. PubMed ID: 27459662
[TBL] [Abstract][Full Text] [Related]
19. Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data.
Campioni M; Agirrezabal I; Hajek R; Minarik J; Pour L; Spicka I; Gonzalez-McQuire S; Jandova P; Maisnar V
Eur J Health Econ; 2020 Mar; 21(2):219-233. PubMed ID: 31673898
[TBL] [Abstract][Full Text] [Related]
20. Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and A.R.R.O.W. Trials.
Dimopoulos MA; Moreau P; Iida S; Huang SY; Takezako N; Chng WJ; Zahlten-Kumeli A; Sersch MA; Li J; Huang M; Lee JH
Int J Hematol; 2019 Oct; 110(4):466-473. PubMed ID: 31388932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
